Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment.
Bardakci M, Karakas H, Bayram D, Avci N, Kitapli S, Ozen M, Aslan F, Koseoglu C, Kadioglu A, Onur ID, Sakalar T, Buyuksimsek M, Alkan A, Ergun Y, Kaya AO, Bilgin B, Yalcin B. Bardakci M, et al. Among authors: bayram d. Sci Rep. 2024 May 9;14(1):10632. doi: 10.1038/s41598-024-61562-w. Sci Rep. 2024. PMID: 38724585 Free PMC article.
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, Oruç Z, Derin S, Turna ZH, Bayram D, Köş FT, Şendur MAN, Sever N, Ercelep Ö, Seyyar M, Kefeli U, Uygun K, Özçelik M, Ön S, Şanlı UA, Canaslan K, Ünek İT, Yücel KB, Özdemir N, Yazıcı O, Güzel HG, Salim DK, Göksu SS, Tatlı AM, Ordu Ç, Selvi O, Sakin A, Büyükbayram ME, Dursun B, Ürün Y, Arak H, Ağdaş G, Uğraklı M, Hendem E, Eryılmaz MK, Bilgin B, Topçu A, Şimşek M, Büyükşimşek M, Akay B, Erdal GŞ, Karataş F, Alan Ö, Çağlayan M, Kahvecioğlu FA, Demirci A, Paksoy N, Çetin B, Gümüş M, Ak N, Aydınalp Y, Paydaş S, Güven DC, Kılıçkap S, Sağlam S. Ünal Ç, et al. Among authors: bayram d. Oncologist. 2023 Oct 3;28(10):875-884. doi: 10.1093/oncolo/oyad257. Oncologist. 2023. PMID: 37676712 Free PMC article.
Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study.
Sekmek S, Karahan I, Ucar G, Ceylan F, Bayram D, Seven I, Bölek H, Ürün Y, Yücel KB, Yazici O, Kadioglu A, Karacin C, Canaslan K, Atag E, Demirer S, Erdem GU, Ergun Y, Atak M, Koksal B, Kiran MM, Turkay DO, Civelek B, Yalcin B, Uncu D. Sekmek S, et al. Among authors: bayram d. Clin Transl Oncol. 2024 Aug;26(8):1878-1885. doi: 10.1007/s12094-024-03410-x. Epub 2024 Mar 7. Clin Transl Oncol. 2024. PMID: 38451412
The Comparison of FLOT and DCF Regimens as Perioperative Treatment for Gastric Cancer.
Uçar G, Sekmek S, Karahan İ, Ergün Y, İsak ÖA, Tunç S, Doğan M, Gürler F, Bayram D, Açıkgöz Y, Esen SA, Civelek B, Köş FT, Bal Ö, Algın E, Eren T, İmamoğlu Gİ, Urakçı Z, Yazıcı O, Özdemir N, Uncu D. Uçar G, et al. Among authors: bayram d. Oncology. 2024 Jul 30:1-6. doi: 10.1159/000540517. Online ahead of print. Oncology. 2024. PMID: 39079501 Free article.
Cabozantinib-induced heart failure.
Sekmek S, Bayram D, Ucar G, Civelek B, Kos FT, Uncu D. Sekmek S, et al. Among authors: bayram d. J Oncol Pharm Pract. 2024 Jan;30(1):225-227. doi: 10.1177/10781552231203703. Epub 2023 Oct 11. J Oncol Pharm Pract. 2024. PMID: 37817663
The HALP score as a prognostic factor in metastatic biliary cancer.
Seven İ, Karahan İ, Köş FT, Bayram D, Sekmek S, Aktürk Esen S. Seven İ, et al. Among authors: bayram d. Clin Transl Oncol. 2024 Sep 13. doi: 10.1007/s12094-024-03702-2. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39271621
Prognostic Significance of HER2 Positivity in Endometrium Cancer.
Sekmek S, Bayram D, Karahan I, Seven I, Perkin P, Muftuoglu KH, Bal O, Yalcin B, Uncu D, Algin E. Sekmek S, et al. Among authors: bayram d. Oncol Res Treat. 2024 Nov 29:1-6. doi: 10.1159/000542900. Online ahead of print. Oncol Res Treat. 2024. PMID: 39616989
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
Sekmek S, Ozsan Çelebi SN, Bayram D, Erol C, Kos FT, Sendur MAN, Altıntas YE, Tuylu T, Yildirim S, Biter S, Kıdı MM, Bayram E, Majidova N, Bayoglu IV, Atak M, Baskurt K, Akbas S, Alkan A, Bayramgil A, Aslan F, Sahin E, Balcik OY, Bayhan AZ, Saray S, Arpaci E, Ergun Y. Sekmek S, et al. Among authors: bayram d. Sci Rep. 2024 Nov 30;14(1):29785. doi: 10.1038/s41598-024-81371-5. Sci Rep. 2024. PMID: 39616250 Free PMC article.
56 results